drugset / Trial / NCT06493604

A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

NCT06493604

Phase 3 Completed 116 enrolled Aldeyra Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

A Randomized, Double-Masked, Vehicle-Controlled Parallel Group Clinical Trial to Assess Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease

Timeline

Start
2024-06-24
Primary completion
2025-02-27
Completion
2025-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Reproxalap Other / unclassified 0.25 %

Indications